Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATHERSYS, INC / NEWATHX · Entity 95922 | Director · CEO | October 04, 2023 | October 06, 2023 |
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | July 09, 2026 | July 10, 2026 |
| Horizon Therapeutics Public Ltd CoHZNP · Entity 109157 | EVP and President, U.S. | April 05, 2021 | April 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATHERSYS, INC / NEW
Report date October 04, 2023 · Filed October 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 285,341 |
Reported balance
After 2023-10-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-10-04 · Tax withholding · Disposed 19,993 · Balance 285,341 F1: Shares withheld from the quarterly vesting of annual restricted stock unit awards related to the tax withholding obligation. F2: Securities beneficially owned are comprised of 285,341 shares of common stock owned which vest quarterly over a four-year period from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld from the quarterly vesting of annual restricted stock unit awards related to the tax withholding obligation.
F2: Securities beneficially owned are comprised of 285,341 shares of common stock owned which vest quarterly over a four-year period from the date of grant.
Cue Biopharma, Inc.
Report date July 09, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,800 |
Reported balance
After 2026-07-09 transaction · row 1
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 21,800 · Balance 21,800 F1: Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date.
Horizon Therapeutics Public Ltd Co
Report date April 05, 2021 · Filed April 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary sharesSEC Table I · non-derivative | Direct | 51,181 |
Ending reported balance
After 2021-04-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-04-05 · Exercise / conversion · Acquired 2,305 · Balance 35,205 Row 2 · 2021-04-05 · Exercise / conversion · Acquired 15,467 · Balance 50,672 Row 3 · 2021-04-05 · Exercise / conversion · Acquired 509 · Balance 51,181 |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.19 · Expires 2027-02-21 | Direct | 0 |
Reported balance
After 2021-04-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-05 · Exercise / conversion · Disposed 2,305 · Balance 0 F1: The option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.52 · Expires 2025-09-22 | Direct | 4,333 |
Reported balance
After 2021-04-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-04-05 · Exercise / conversion · Disposed 15,467 · Balance 4,333 F1: The option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.23 · Expires 2026-05-03 | Direct | 3,441 |
Reported balance
After 2021-04-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-04-05 · Exercise / conversion · Disposed 509 · Balance 3,441 F1: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 10, 2026 23:37 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock | 21,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001820365-26-000009 · form4-07102026_110706.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,800 F1 · shares: Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date. Read SEC document |
| May 30, 2026 Filed Jun 8, 2026 20:25 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (Right to Buy) · Derivative | 1,626 | $0.00 Strike: $21.90 | $0.00 |
DisclosureSEC source: 0001820365-26-000006 · form4-06082026_080603.xml · derivative · entry 1 Camardo Daniel A. · CIK 0001820365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,626 Underlying: Common Stock · 1,626 shares Expires 2036-05-29 F1 · derivative.exercise_date: The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 17:28 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | Tax withholdingCommon Stock | 19,993 | $0.44 | $8,796.92 |
DisclosureSEC source: 0001437749-23-027868 · rdgdoc.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,341 F1 · shares: Shares withheld from the quarterly vesting of annual restricted stock unit awards related to the tax withholding obligation. F2 · balance_after: Securities beneficially owned are comprised of 285,341 shares of common stock owned which vest quarterly over a four-year period from the date of grant. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 09:53 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | Tax withholdingCommon Stock | 19,993 | $0.91 | $18,273.60 |
DisclosureSEC source: 0001368148-23-000069 · wf-form4_168865156205949.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,334 F1 · shares: Shares withheld from the quarterly vesting of annual restricted stock unit awards related to the tax withholding obligation. F2 · balance_after: Securities beneficially owned are comprised of (1) 239,461 shares of common stock owned and (2) unvested restricted stock units aggregating 65,873 related to annual awards, which vest quarterly over a four-year period from date of grant. Read SEC document |
| April 04, 2023 Filed Apr 5, 2023 16:04 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | Tax withholdingCommon Stock | 19,993 | $1.00 | $19,993.00 |
DisclosureSEC source: 0001368148-23-000031 · wf-form4_168072507291634.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,327 F1 · shares: Shares withheld from the quarterly vesting of annual restricted stock unit awards related to the tax withholding obligation. F2 · balance_after: Securities beneficially owned are comprised of (1) 193,581 shares of common stock owned and (2) unvested restricted stock units aggregating 131,746 related to annual awards, which vest quarterly over a four-year period from date of grant. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 18:05 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | Tax withholdingCommon Stock | 23,484 | $0.85 | $19,961.40 |
DisclosureSEC source: 0001368148-23-000007 · wf-form4_167304630532391.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,320 F1 · shares: Shares withheld from the quarterly vesting of annual restricted stock unit awards related to the tax withholding obligation. F2 · balance_after: Securities beneficially owned are comprised of (1) 147,701 shares of common stock owned and (2) unvested restricted stock units aggregating 197,619 related to annual awards, which vest quarterly over a four-year period from the date of grant. Read SEC document |
| November 22, 2022 Filed Nov 22, 2022 15:53 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | PurchaseCommon Stock | 100,000 | $0.55 | $54,960.00 |
DisclosureSEC source: 0001368148-22-000157 · wf-form4_166915042016905.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at $0.54 and $0.55. The reporting person undertakes to provide to Athersys, Inc., any security holder of Athersys, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 12:56 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantCommon Stock | 263,492 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-033112 · doc4.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,804 F1 · shares: Represents the exempt acquisition of 263,492 restricted stock units that in general will vest in substantially equal quarterly installments over one year from the date of grant of October 4, 2022, subject generally to the Reporting Person's continued employment with the Issuer or its subsidiaries. F2 · balance_after: On August 26, 2022, the Issuer effected a 1-for-25 reverse stock split of its Common Stock (the "Reverse Stock Split"), resulting in a decrease in the Reporting Person's ownership by 127,488 shares. Read SEC document |
| March 17, 2022 Filed Mar 17, 2022 11:09 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | PurchaseCommon Stock | 132,800 | $0.77 | $102,256.00 |
DisclosureSEC source: 0001368148-22-000023 · wf-form4_164752975353681.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,800 Read SEC document |
| February 14, 2022 Filed Feb 14, 2022 17:41 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantStock Option (right to purchase) · Derivative | 4,000,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001368148-22-000010 · wf-form4_164487844952952.xml · derivative · entry 1 Camardo Daniel A. · CIK 0001820365 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000,000 Underlying: Common Stock · 4,000,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: One-fourth of the option vests on the one-year anniversary date of the grant and the remainder vests in equal monthly installments over the following three years. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 17:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 509 | $0.00 Strike: $15.23 | $0.00 |
DisclosureSEC source: 0001209191-21-025270 · doc4.xml · derivative · entry 6 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,441 Underlying: Ordinary shares · 509 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 17:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 15,467 | $0.00 Strike: $25.52 | $0.00 |
DisclosureSEC source: 0001209191-21-025270 · doc4.xml · derivative · entry 5 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,333 Underlying: Ordinary shares · 15,467 shares Expires 2025-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 17:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 2,305 | $0.00 Strike: $17.19 | $0.00 |
DisclosureSEC source: 0001209191-21-025270 · doc4.xml · derivative · entry 4 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 2,305 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 17:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary shares | 509 | $15.23 | $7,752.07 |
DisclosureSEC source: 0001209191-21-025270 · doc4.xml · nonDerivative · entry 3 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 17:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary shares | 15,467 | $25.52 | $394,717.84 |
DisclosureSEC source: 0001209191-21-025270 · doc4.xml · nonDerivative · entry 2 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 17:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary shares | 2,305 | $17.19 | $39,622.95 |
DisclosureSEC source: 0001209191-21-025270 · doc4.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 17:11 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 3,517 | $86.87 | $305,521.79 |
DisclosureSEC source: 0001209191-21-023819 · doc4.xml · nonDerivative · entry 4 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,900 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2021. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.60 to $87.33 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 17:11 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 2,986 | $85.88 | $256,437.68 |
DisclosureSEC source: 0001209191-21-023819 · doc4.xml · nonDerivative · entry 3 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,417 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2021. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.55 to $86.545 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 17:11 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 4,594 | $84.97 | $390,352.18 |
DisclosureSEC source: 0001209191-21-023819 · doc4.xml · nonDerivative · entry 2 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,403 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.53 to $85.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 17:11 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 1,803 | $83.58 | $150,694.74 |
DisclosureSEC source: 0001209191-21-023819 · doc4.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,997 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.23 to $84.095 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 18:18 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013376 · doc4.xml · derivative · entry 3 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,300 shares Expires 2021-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 18:18 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 576 | $88.87 | $51,189.12 |
DisclosureSEC source: 0001209191-21-013376 · doc4.xml · nonDerivative · entry 2 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,800 Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 18:18 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 1,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-013376 · doc4.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionPerformance Restricted Stock Units (PSUs) · Derivative | 3,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-005003 · doc4.xml · derivative · entry 3 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,220 shares Expires 2021-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 1,427 | $77.43 | $110,492.61 |
DisclosureSEC source: 0001209191-21-005003 · doc4.xml · nonDerivative · entry 2 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,076 Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 3,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-005003 · doc4.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:12 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 4,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002418 · doc4.xml · derivative · entry 6 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,708 Underlying: Ordinary Shares · 4,354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:12 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 10,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002418 · doc4.xml · derivative · entry 5 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,626 Underlying: Ordinary Shares · 10,626 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F4 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:12 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 5,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002418 · doc4.xml · derivative · entry 4 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,634 shares Expires 2021-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:12 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 9,230 | $73.28 | $676,374.40 |
DisclosureSEC source: 0001209191-21-002418 · doc4.xml · nonDerivative · entry 2 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,283 Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:12 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 20,614 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-002418 · doc4.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · balance_after: Includes 1,070 ordinary shares of the Issuer acquired by the reporting person on December 1, 2020 pursuant to an employee stock purchase program. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:12 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 20,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002418 · doc4.xml · derivative · entry 3 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,957 Underlying: Ordinary Shares · 20,957 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| November 06, 2020 Filed Nov 6, 2020 18:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 3,500 | $76.76 | $268,663.15 |
DisclosureSEC source: 0001209191-20-057343 · doc4.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,829 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.67 to $76.915 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2020 Filed Oct 22, 2020 18:14 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055603 · doc4.xml · derivative · entry 3 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The restricted stock units vested in two annual installments of 10,000 shares on each anniversary of the grant date (October 1, 2018). F2 · derivative.expiration_date: The restricted stock units vested in two annual installments of 10,000 shares on each anniversary of the grant date (October 1, 2018). Read SEC document |
| October 01, 2020 Filed Oct 22, 2020 18:14 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 4,460 | $80.42 | $358,673.20 |
DisclosureSEC source: 0001209191-20-055603 · doc4.xml · nonDerivative · entry 2 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,329 Read SEC document |
| October 01, 2020 Filed Oct 22, 2020 18:14 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055603 · doc4.xml · nonDerivative · entry 1 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,789 Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 13:27 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 17,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-044994 · doc4.xml · derivative · entry 1 Camardo Daniel A. · CIK 0001820365 · EVP and President, U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,102 Underlying: Ordinary Shares · 17,102 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of August 1, 2020. F2 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of August 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.